Michael Gutch, Ph.D.

Chief Business Officer and Chief Financial Officer, Entasis Therapeutics

Mike Gutch is currently Chief Business Officer and Chief Financial Officer at Entasis Therapeutics. Prior to Entasis, he served as an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for mergers and acquisitions, divestments, and strategic equity investments. Previously, Dr. Gutch had experience as both a corporate and private venture capital investor as a Managing Director of MedImmune Ventures, a Director with H.I.G. BioVentures, and a Principal with Lilly Ventures, the corporate venture capital arm of Eli Lilly & Company. While at Eli Lilly, Dr. Gutch was also in the Corporate Financing and Investment Banking group, where he focused on mergers and acquisitions and licensing transactions.

Dr. Gutch earned his Ph.D. in Cellular and Molecular Pathology from the State University of New York at Stony Brook and was a post-doctoral research fellow at both UCSF and the Cold Spring Harbor Laboratories. He earned his M.B.A. in finance from Indiana University. Mike also serves as a member of the Board of Directors for Southeast BIO, a member of the Johns Hopkins Alliance for Science & Technology Development, and a member of the Emory University New Venture Advisory Board.

Team members

David Chiswell, Ph.D.

Chairman of the Board, Albireo; Chief Executive Officer, Kymab

Julia R. Brown

Former Executive Vice President and Advisor to the CEO, Amylin Pharmaceuticals (retired)

Michael Gutch, Ph.D.

Chief Business Officer and Chief Financial Officer, Entasis Therapeutics

Roger A. Jeffs, Ph.D.

Former President and co-CEO, United Therapeutics (retired)

Heather Preston, M.D.

Partner & Managing Director, TPG Biotech

Davey S. Scoon

Chair of the Board of Trustees, Allianz Global Investors

Ron Cooper

President and Chief Executive Officer